Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Comment on "Robotic-Assisted vs Open Kidney Transplantation: A Systemic Review and Meta-Analysis of Propensity-Matched Studies".

Urology·2025
Same author

Editorial Comment on "Living Donor Nephrectomy: Analysis of Trends and Outcomes From a Contemporary National Dataset".

Urology·2024
Same author

Editorial Comment on "Renal Autotransplantation: Association Between Preoperative Disease Duration and Surgical Outcomes".

Urology·2024
Same author

Editorial Commentary.

Urology practice·2023
Same author

Editorial Commentary.

Urology practice·2023
Same author

Invited Commentary: Kidney Transplantation and Obesity: Are There Any Differences in Outcomes?

World journal of surgery·2022

Related Experiment Videos

Treating erectile dysfunction in renal transplant recipients.

John M Barry1

  • 1Division of Urology and Renal Transplantation, The Oregon Health and Science University, Portland, Oregon 97239, USA. barryj@ohsu.edu

Drugs
|May 10, 2007
PubMed
Summary

Erectile dysfunction is a common issue for kidney transplant recipients. Treatments like testosterone therapy, sildenafil, alprostadil injections, and penile prostheses offer effective, patient-specific solutions with minimal impact on transplant health.

Related Experiment Videos

Area of Science:

  • Nephrology
  • Urology
  • Transplantation Medicine

Background:

  • Erectile dysfunction (ED) is prevalent in male kidney transplant recipients.
  • Contributing factors include comorbidities, surgical effects, medications, psychological issues, and relationship dynamics.
  • A tailored, treatment-focused approach is essential for managing ED in this population.

Purpose of the Study:

  • To review and synthesize current treatment strategies for erectile dysfunction in kidney transplant recipients.
  • To evaluate the safety and efficacy of various ED treatments in the context of immunosuppression and renal allograft function.

Main Methods:

  • Review of existing literature on ED treatments in kidney transplant recipients.
  • Analysis of the impact of specific medications (e.g., sildenafil, testosterone) and procedures (e.g., intracavernosal injections, penile prostheses) on renal function and drug concentrations.
  • Assessment of treatment outcomes and adverse effects.

Main Results:

  • Testosterone replacement therapy may benefit hypogonadal patients post-transplant.
  • Sildenafil (a phosphodiesterase-5 inhibitor) at recommended doses does not significantly affect calcineurin inhibitor levels or renal function, though tacrolimus may alter sildenafil pharmacokinetics.
  • Daily sildenafil use may lower blood pressure in hypertensive patients on tacrolimus.
  • Intracavernosal alprostadil (alone or with papaverine/phentolamine) is effective and safe for renal function and calcineurin inhibitor levels.
  • Penile prosthesis implantation is a viable option post-pelvic organ transplantation with low infection risk.

Conclusions:

  • Patient-specific treatment plans are crucial for managing ED in kidney transplant recipients.
  • Several effective and generally safe treatment options exist, including hormonal therapy, oral medications, intracavernosal injections, and surgical interventions.
  • Careful consideration of drug interactions and patient comorbidities is necessary for optimal outcomes.